TG aims for accelerated approval of lymphoma candidate

TG Therapeutics Inc. (NASDAQ:TGTX) added $1.61 (31%) to $6.80 on Thursday after reporting that umbralisib (TGR-1202) met the primary endpoint in a cohort of marginal zone lymphoma patients in a pivotal Phase IIb trial. The biotech now plans to seek accelerated approval of the phosphoinositide 3-kinase δ (PI3K δ) inhibitor.